SLC1A2 and breast carcinoma: In addition to neurological diseases, although EAAT2 is mainly expressed in the brains, three tissue-specific tumors (gastric, colorectal and breast cancers) are related to the enhanced expression of EAAT2, which is associated with resistance to chemotherapeutic and endocrine therapies37–40.